A cluster of rare-disease acquisitions surfaced as biopharma M&A activity ramped into the second half of the year. Deal coverage highlighted proposed takeouts including Vertex’s bid for Crinetics, United Therapeutics’ planned purchase of Thymmune, and Ipsen’s purchase of Memo, with the combined announced value approaching $13 billion. The transactions collectively show a continued premium on late-stage rare-disease franchises and pipeline programs where specialty commercial capabilities and payer alignment can accelerate time-to-revenue. Rare endocrine and regenerative immunology were particular targets in the lineup, spanning from marketed therapies to preclinical platforms. Investors will be watching whether these deals translate into faster clinical execution and clearer regulatory pathways, especially as many assets are positioned to expand beyond initial single-indication strategies.